← FDATracker
HomeAdverse Events

TYSABRI Adverse Event: Lung neoplasm malignant

TYSABRI Adverse Event: Lung neoplasm malignant is one of 4,500 adverse events in the FDATracker dataset. Key details — Primary drug: TYSABRI; Product category: Drug; Primary reaction: Lung neoplasm malignant.

Primary drugTYSABRI
Product categoryDrug
Primary reactionLung neoplasm malignant
All reactionsLung neoplasm malignant; Pneumonia
SeriousnessSerious
Patient outcomeUnknown
Patient sexMale
All drugs reportedTYSABRI; TYSABRI; TYSABRI
Reporter countryUS
Reporter type3
Report date20140313
Report ID10005508

🔍 Search all adverse events →